OTCPK:HTLZ.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Hamilton Thorne's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HTLZ.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.5%

HTLZ.F

1.1%

US Medical Equipment

1.0%

US Market


1 Year Return

33.3%

HTLZ.F

15.4%

US Medical Equipment

13.6%

US Market

Return vs Industry: HTLZ.F exceeded the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: HTLZ.F exceeded the US Market which returned 13.6% over the past year.


Shareholder returns

HTLZ.FIndustryMarket
7 Day0.5%1.1%1.0%
30 Day-2.8%1.5%-0.4%
90 Day16.7%12.0%8.9%
1 Year33.3%33.3%16.4%15.4%16.2%13.6%
3 Year82.9%82.9%73.3%68.8%40.2%30.8%
5 Year422.4%422.4%149.6%130.6%89.6%68.2%

Price Volatility Vs. Market

How volatile is Hamilton Thorne's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hamilton Thorne undervalued compared to its fair value and its price relative to the market?

3.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HTLZ.F ($1.05) is trading below our estimate of fair value ($1.09)

Significantly Below Fair Value: HTLZ.F is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: HTLZ.F is poor value based on its PE Ratio (161.8x) compared to the US Medical Equipment industry average (49.4x).

PE vs Market: HTLZ.F is poor value based on its PE Ratio (161.8x) compared to the US market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: HTLZ.F is poor value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: HTLZ.F is good value based on its PB Ratio (3x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Hamilton Thorne forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

161.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HTLZ.F's forecast earnings growth (161.2% per year) is above the savings rate (2.2%).

Earnings vs Market: HTLZ.F's earnings (161.2% per year) are forecast to grow faster than the US market (23.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HTLZ.F's revenue (14.4% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: HTLZ.F's revenue (14.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HTLZ.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Hamilton Thorne performed over the past 5 years?

14.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HTLZ.F has a large one-off loss of $397.8K impacting its June 30 2020 financial results.

Growing Profit Margin: HTLZ.F's current net profit margins (2.2%) are lower than last year (5.7%).


Past Earnings Growth Analysis

Earnings Trend: HTLZ.F's earnings have grown by 14.1% per year over the past 5 years.

Accelerating Growth: HTLZ.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HTLZ.F had negative earnings growth (-53.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.2%).


Return on Equity

High ROE: HTLZ.F's Return on Equity (1.7%) is considered low.


Next Steps

Financial Health

How is Hamilton Thorne's financial position?


Financial Position Analysis

Short Term Liabilities: HTLZ.F's short term assets ($30.8M) exceed its short term liabilities ($8.8M).

Long Term Liabilities: HTLZ.F's short term assets ($30.8M) exceed its long term liabilities ($9.0M).


Debt to Equity History and Analysis

Debt Level: HTLZ.F's debt to equity ratio (21.3%) is considered satisfactory.

Reducing Debt: HTLZ.F had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: HTLZ.F's debt is well covered by operating cash flow (35.9%).

Interest Coverage: HTLZ.F's interest payments on its debt are not well covered by EBIT (2.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Hamilton Thorne current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HTLZ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HTLZ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HTLZ.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTLZ.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTLZ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.8yrs

Average management tenure


CEO

David Wolf

9yrs

Tenure

US$438,025

Compensation

Mr. David B. Wolf has been the Chief Executive Officer of Hamilton Thorne Ltd. since September 2011 and serves as its President. From October 1997 to August 2011, Mr. Wolf was co-founder and Managing Direc ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD438.03K) is about average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Meg Spencer
Co-Founder & Chairman of the Boardno dataUS$20.00k0.99%
$ 1.4m
David Wolf
President9yrsUS$438.03k1.09%
$ 1.5m
Diarmaid Douglas-Hamilton
Co-Founder10.92yrsUS$197.55k0.72%
$ 1.0m
Michael Bruns
VP of Finance & CFO9.75yrsUS$233.88k0.38%
$ 536.2k
Fabian Sell
Chief Executive Officer of Gynemedno dataUS$270.90kno data
Keith Edwards
Senior VP & GM4.83yrsUS$171.70k0%
$ 0
Eric Dorman
President of Embryotech Laboratories Incno dataUS$215.25kno data

9.8yrs

Average Tenure

Experienced Management: HTLZ.F's management team is seasoned and experienced (9.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Meg Spencer
Co-Founder & Chairman of the Boardno dataUS$20.00k0.99%
$ 1.4m
David Wolf
President9yrsUS$438.03k1.09%
$ 1.5m
Diarmaid Douglas-Hamilton
Co-Founder10.92yrsUS$197.55k0.72%
$ 1.0m
Robert Potter
Independent Director10.92yrsUS$29.50k0.016%
$ 22.5k
Daniel Thorne
Independent Director10.92yrsUS$22.00k14.49%
$ 20.5m
Bruno Maruzzo
Independent Director13.5yrsUS$28.50k0.41%
$ 581.1k
Dean Gendron
Independent Director13.58yrsUS$30.00k0.15%
$ 214.3k
David Zhang
Member of Scientific Advisory Boardno datano datano data
Fred Kramer
Chairman of Scientific Advisory Boardno datano datano data
Alan Trounson
Member of Scientific Advisory Boardno datano datano data
David Sable
Independent Director3.58yrsUS$20.00k0.019%
$ 27.3k
Barbara Talamo
Member of Scientific Advisory Boardno datano datano data

10.9yrs

Average Tenure

68yo

Average Age

Experienced Board: HTLZ.F's board of directors are seasoned and experienced ( 10.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.


Top Shareholders

Company Information

Hamilton Thorne Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hamilton Thorne Ltd.
  • Ticker: HTLZ.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$186.795m
  • Listing Market Cap: CA$141.549m
  • Shares outstanding: 138.37m
  • Website: https://www.hamiltonthorne.ltd

Location

  • Hamilton Thorne Ltd.
  • 100 Cummings Center
  • Suite 465E
  • Beverly
  • Massachusetts
  • 1915
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTLTSXV (TSX Venture Exchange)YesCommon StockCACADNov 2009
HTLZ.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2009
0ZMDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2009

Biography

Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. It of ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 05:56
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.